FDA endorses Alzheimer’s drug donanemab
Image credit: averey via Unsplash
The US Food and Drug Administration (FDA) has endorsed Eli Lilly’s early-stage Alzheimer’s drug, donanemab, which has shown promising results in slowing cognitive decline. Targeting amyloid plaques in the brain, the drug has been deemed safe and effective by the FDA. If approved, donanemab would be the second drug available to help individuals in the early stages of Alzheimer's improve their quality of life, offering new hope to millions affected by this condition.
Source
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527. doi:10.1001/jama.2023.13239